• 2002 Ph.D. Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong
• 1995 M.S. Department of Biology, Tunghai University, Taiwan
• 1992 B.S. Department of Biology, Tunghai University, Taiwan

• Cancer Immuno-Epigenomics 癌症免疫表基因體學
• Cancer Systems Biology 系統生物學
• Bioinformatics 生物資訊

•  Professor, Department of Biomedical Sciences, National Chung Cheng University
•  Associate Dean, College of Sciences, National Chung Cheng University
•  Director, Epigenomics and Human Diseases Research Center, National Chung Cheng University
•  Director, Division of International Students,Office of International Affairs, National Chung Cheng University

• 2016-Professor, Department of Life Science, National Chung Cheng University, Chia-Yi, Taiwan
• 2012-2016 Associate Professor, Department of Life Science, National Chung Cheng University, Chia-Yi, Taiwan
• 2007-2012 Assistant Professor, Department of Life Science, National Chung Cheng University, Chia-Yi, Taiwan
• 2004-2007 Postdoctoral Researcher, Human Cancer Genetics, The Ohio State University, Columbus, Ohio, USA (Mentor: Prof. Tim H.M. Huang)
• 2002-2004 Postdoctoral Fellow, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong (Mentor: Prof. Francis K.L. Chan)

• Epigenetic and immunotherapy in human cancer.
• DNA methylation as biomarkers in human cancer.

• Epigenetic and immunotherapy in human cancer.
• DNA methylation as biomarkers in human cancer.

• 2001 AACR Ito-En scholar-in-training award
• 2002 Sir Edward Youde Memorial Fellowship
• 2006 AACR-Aflac, Incorporated scholar-in-training award
• 2009 AACR Ito-En scholar-in-training award (周建良, Ph.D. student)
• 2011 CCU Distinguish Lecturer for General Education 通識教育教師獎
• 2021 CCU Outstanding Distinguish Research Paper Award 論文傑出獎

Complete list of publications:

Web of Science: https://www.webofscience.com/wos/author/record/F-9615-2018

Journal Paper (Selected publications from a total of 119)

1. Guthula LS, Yeh KT, Huang WL, Chen CH, Huang CJ, Chau LK*, Chan MW* and Lin SH*. Quantitative and amplification-free detection of SOCS-1 CpG methylation percentage analyses in gastric cancer by fiber optic nanoplasmonic biosensor. Biosensors and Bioelectronics 214:114540, Oct, 2022

2. Lin GL, Tsai LH, Kuppen PJK*, Chan MW*. Firing up Cold Tumors-Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy. Epigenomes 5:11, May 2021 (Editorial)

3. Jou YC, Lin GL, Lin HY, Huang WH, Chuang YM, Lin RI, Chen PC, Wu SF, Shen CH*, Chan MW*. Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma. Cancer Cell International 21:226, Apr 2021

4. Chen PC, Yu CC, Huang WY, Huang WH, Chuang YM, Lin RI, Lin JM, Lin HY, Jou YC, Shen CH*, Chan MW*. c-Myc Acts as a Competing Endogenous RNA to Sponge miR-34a, in the Upregulation of CD44, in Urothelial Carcinoma. Cancers 11: 1457, 2019.

5. Gasser A, Chen YW, Audebrand A, Daglayan A, Charavin M, Escoubet B, Karpov P, Tetko I, Chan MW, Cardinale D, Désaubry L and Nebigil CG. Prokineticin Receptor-1 Signaling Inhibits Dose- and Time-Dependent Anthracycline-Induced Cardiovascular Toxicity Via Myocardial and Vascular Protection. JACC: CardioOncology 1:84-102, 2019.

6. Xiong L, Wu F, Wu Q, Xu L, Cheung OK, Kang W, Mok MT, Szeto LL, Lun CY, Lung RW, Zhang J, Yu KH, Lee SD, Huang G, Qang CM, Liu J, Yu Z, Yu DY, Chou JL, Huang WH, Feng B, Cheung YS, Lai PB, Tan P, Wong N, Chan MW, Huang TH, Yip KY, Cheng AS, To KF.  Aberrant Enhancer Hypomethylation Drives Hepatic Carcinogenesis through Global Transcriptional Reprogramming. Nature Communications, 10:335, 2019.

7. Hsieh HY, Jou YC, Tung CL, Tsai YS, Wang YH, Chi CL, Lin RI, Hung SK, Chuang YM, Wu SF, Li C, Shen CH, Chan MW, Hsu CD. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.  Oncogene   37:673-686, 2018

8. Hsieh HY, Shen CH, Lin RI, Feng YM, Huang SY, Wang YH, Wu SF, Hsu CD, and Chan MW.  Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways.  Cancer Letters   370:56-65, 2016.

9. Chou JL, Huang RL, Shay J, Chen LY, Lin SJ, Yan PS, Chao WT, Lai YH, Lai YL, Chao TK, Lee CI, Tai CK, Wu SF, Nephew KP, Huang TH, Lai HC*, and Chan MW.  Hypermethylation of the TGF-β target, ABCA1 is associated with poor prognosis in ovarian cancer patients.  Clinical Epigenetics   7:1, 2015

10. Chan MW, Chang CB, Tung CH, Sun J, Suen JL, Wu SF. Low-dose 5-aza-2’-deoxycytidine pretreatment inhibits experimental autoimmune encephalomyelitis by induction of regulatory T cells.  Molecular Medicine   20:248-256, 2014.

11. Cheng AS, Li MS, Kang W, Cheng VY, Chou JL, Lau SS, Go MY, Lee CC, Ling TK, Ng EK, Yu J, Huang TH, To KF, Chan MW, Sung JJ, Chan FK.  Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis.  Gastroenterology   144:122-133, 2013

12. Yeh KT, Chen TH, Yang HW, Chou JL, Chen LY, Yeh CM, Chen YH, Lin RI, Su HY, Chen GC, Deatherage DE, Huang YW, Yan PS, Lin HJ, Nephew KP, Huang TH, Lai HC, Chan MW. Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.  Epigenetics   6:727-739, 2011

13. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, Liu JQ, Love R, Liu CG, Godfrey V, Shen R, Huang THM, Yang T, Park BK, Wang CY, Zheng P and Liu Y.   FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene.  Cell   129: 1275-86, 2007.

14. Cheng AS, Jin VX, Fan M, Smith LT, Liyanarachchi S, Yan PS, Leu YW, Chan MW, Plass C, Nephew KP, Davuluri RV, and Huang THM.  Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor α- responsive promoters.  Molecular Cell   21:393-404, 2006.

15. Chan MW, Chan LW, Tang NLS, Lee TL, Tong JHM, Lo KW, Cheung HY, Wong WS, Chan PSF, Lai FMM, and To KF.  Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.  Clinical Cancer Research  8: 464-470, 2002.